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ABSTRACT: Glial cells express acetylcholine recep-
tors. In particular, rat Schwann cells express different
muscarinic receptor subtypes, the most abundant of which
is the M2 subtype. M2 receptor activation causes a reversi-
ble arrest of the cell cycle. This negative effect on Schwann
cell proliferation suggests that these cells may possibly pro-
gress into a differentiating program. In this study we ana-
lyzed the in vitromodulation, by the M2 agonist arecaidine,
of transcription factors and specific signaling pathways
involved in Schwann cell differentiation. The arecaidine-
induced M2 receptor activation significantly upregulates
transcription factors involved in the promyelinating phase
(e.g., Sox10 and Krox20) and downregulates proteins
involved in the maintenance of the undifferentiated state
(e.g., c-jun, Notch-1, and Jagged-1). Furthermore, arecai-
dine stimulation significantly increases the expression of
myelin proteins, which is accompanied by evident changes
in cell morphology, as indicated by electron microscopy
analysis, and by substantial cellular re-distribution of actin
and cell adhesion molecules. Moreover, ultrastructural and
morphometric analyses on sciatic nerves of M2/M4 knock-
out mice show numerous degenerating axons and clear
alterations in myelin organization compared with wild-
type mice. Therefore, our data demonstrate that acetylcho-
line mediates axon-glia cross talk, favoring Schwann cell
progression into a differentiated myelinating phenotype
and contributing to compact myelin organization. VC 2013
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INTRODUCTION
Large diameter axons are surrounded by myelin
sheaths, which promote rapid conduction of nerve
impulses and increase efficiency of nervous system
communication. Myelin sheaths form during develop-
ment and consist of compact spiral wraps of plasma
membranes, which are supplied by oligodendrocytes
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(OLs) in the central nervous system (CNS) and by
Schwann cells (SCs) in the peripheral nervous system
(PNS). Myelinating glial cells and their target axons
form intimate units, actively regulating each other’s
phenotype. During development, glial cells provide
paracrine signals that support neuron survival and
define both specific molecular domains on the axo-
lemma and axonal diameter (Mirsky et al., 2008). In
turn, axons provide signals regulating glial cell prolif-
eration, survival, differentiation and myelin formation
(Jessen and Mirsky, 2010; Taveggia et al., 2010).
Signals controlling SC development include sev-
eral factors, such as endothelin, histamine and neure-
gulins (NRGs), and adhesion molecules (N-CAM,
MAG, GAP-43) (Birchmeier and Nave, 2008; Wood-
hoo and Sommer, 2008). Some transcription factors,
such as Sox10, Krox24, and Scip/Oct6, are also
required for SC specification and remain active dur-
ing their proliferation (Svaren and Meijer, 2008).
When SCs begin to differentiate, the expression of
the master regulator gene Sox10 increases and, in
turn, upregulates Krox20 expression (Topilko et al.,
1997). The concomitant increase in both transcription
factors upregulates the expression of typical myelin-
associated proteins, such as P0, the myelin basic pro-
tein (MBP) and PMP22 (Peirano et al., 2000;
LeBlanc et al., 2006; Svaren and Meijer, 2008).
In adulthood, neuron-glia interactions are required
to maintain axonal function and myelin integrity. In
the PNS, axonal damage alters this relationship by
promoting SC dedifferentiation, myelin reabsorption
and axon regeneration. Dedifferentiation is the most
relevant feature affecting myelinating SCs; in fact, in
these conditions, these cells re-enter the cell cycle
and acquire an immature phenotype (Jessen and Mir-
sky, 2005, 2008). This switch into a proliferative
state represents an important step in the re-
establishment of an environment favorable to nerve
fiber regeneration. This dedifferentiation step is regu-
lated by activation of c-jun and Notch-1 pathways
(Arthur-Farraj et al., 2012; Fontana et al., 2012;
Woodhoo et al., 2012).
Increasing evidences suggest that neurotrans-
mitters can regulate neuron-glia cross-talk (Fields
and Stevens-Graham, 2002; Loreti et al., 2007; Mag-
naghi et al., 2009). Glial cells express receptors for
different neurotransmitters, indicating they might be
involved in the modulation of glial cell survival, pro-
liferation and differentiation (Magnaghi et al., 2004;
Loreti et al., 2006). Acetylcholine (ACh) is an impor-
tant neurotransmitter in both the CNS and PNS,
whereas its additional function as a hormone has
been described in several tissues, such as keratino-
cytes, lymphocytes and bronchial epithelia (Grando
et al., 2006; Kawashima et al., 2004; Proskocil et al.,
2004). Moreover, several studies indicate that musca-
rinic receptor activation modulates proliferation and
survival of different glial cells, among which astro-
cytes and OLs (Murphy et al., 1986; Ragheb et al.,
2001; De Angelis et al., 2012). We previously dem-
onstrated that SCs are cholinoceptives, as they
express several muscarinic ACh receptor subtypes. In
particular, the expression of the M2 receptor is abun-
dant and persists in mature SCs (Bernardini et al.,
1999; Loreti et al., 2006, 2007). Activation of M2
receptors, by exposing cultured SCs to its agonist are-
caidine, causes an arrest of SC proliferation. This
block is reversible, as removing arecaidine from the
culture medium enables SCs to recover their ability
to proliferate (Loreti et al., 2007). These results
prompted us to further investigate the involvement of
M2 receptor activation in the modulation of SC dif-
ferentiation. We, therefore, analyzed the effects of
arecaidine treatment on the expression of several
markers of SC differentiation (i.e., the TFs Sox10
and Krox20 and the myelin proteins P0, PMP22, and
MBP) and dedifferentiation (i.e., c-jun, Notch-1, and
Jagged-1). Our results show that M2 receptor activa-
tion upregulates promyelinating factors, which pro-
mote SC differentiation towards a myelinating
phenotype, while it downregulates several factors
involved in SC proliferation. The role of M2 receptors
in myelin formation was also evaluated by transmis-
sion electron microscopy (TEM) and morphometric
analysis of the sciatic nerve of M2/M4 knock-out
mice.
MATERIALS AND METHODS
Ethics Statement
This study was carried out in accordance with the guide-
lines laid down by the European Community Council
Directive 86/609/EEC of November 24, 1986. The protocol
was approved by The Italian Ministry of Health. M2/M4
muscarinic receptor double knock-out mice were kindly
provided by Dr. J€urgen Wess (NIH, Bethesda, MD).
Cell Cultures
SC primary cultures were obtained from sciatic nerves dis-
sected from 2-day-old Wistar pups, according to the proto-
col described by Brockes (1987) and modified by Davis
and Stroobant (1990). In brief, sciatic nerves were digested
with trypsin/collagenase (Type I, Sigma-Aldrich, St. Louis,
MA) and seeded into T25 flasks with fresh DMEM contain-
ing 10% fetal bovine serum (FBS, Sigma-Aldrich).
To selectively remove fibroblasts, cells were treated with
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1 mM cytosine arabinoside (AraC, Sigma-Aldrich) for 48 h
and then with anti-Thy 1.1 (1:1000, Serotec, Bio-Rad
group, Hercules, CA) and rabbit complement (1:2 v/v)
(Cedarlane, ON, Canada). SCs were then amplified in
DMEM, 10% FCS, 5 mM forskolin (Fsk; Sigma-Aldrich)
and bovine pituitary extract (1:150, Sigma-Aldrich), and
maintained in DMEM, 10% FBS and 2 mM Fsk during sub-
sequent experiments.
Drug Treatments
SCs were incubated in the presence of the M2 selective
agonist arecaidine (Sigma-Aldrich) (final concentration 100
mM) (Loreti et al., 2007) for different times, according to
the experimental plan (30 min, 1 h, 6 h, 24 h, and 48 h).
Arecaidine is an alkaloid extracted from areca nuts; this
type of alkaloids binds to all cholinergic receptors, but are-
caidine acts as an agonist for atrial M2 muscarinic receptor
(Barlow et al., 1985). Moreover, by pharmacological com-
petition with selective M2 antagonists (gallamine or
methoctramine) and silencing of M2 receptors by siRNAs,
we have previously demonstrated that arecaidine is able to
activate M2 receptor subtypes in different cell types (i.e.,
Schwann cells, OLs and glioblastoma cells) (Loreti et al.,
2007; De Angelis et al., 2012; Ferretti et al., 2013).
Real-Time RT-PCR
Total RNA was extracted using Tri-reagent (Sigma-
Aldrich) following manufacturer’s instructions. Two
micrograms of RNA from each sample were reverse tran-
scribed for 60 min at 37C with 1 lg of random hexamers
(Promega Italia, Mi, Italy) as primers and 200 U of
Moloney Murine Leukemia Virus (M-MLV) reverse
transcriptase (Promega). Real-time Reverse Transcribed-
Polymerase Chain Reaction (RT-PCR) analysis was per-
formed by measuring the incorporation of SyBRGreen
dye (Resnova, Genzano, RM, Italy) on the I Cycler IQTM
Multi-Color Real-Time PCR Detection system (Bio-
Rad). The sequences of the primers used are reported in
Table 1. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as the internal control and all sam-
ples were run in triplicate. Results represent the mean of
at least three independent experiments. Quantification
was performed using the 22DDCt method (Livak and
Schmittgen, 2001).
Western Blot
Protein samples were extracted in either RIPA buffer (50
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 13 prote-
ase inhibitor cocktail, Sigma-Aldrich) or Laemmli sample
buffer (Bio-Rad) with 20% b-mercaptoethanol (depending
on the experimental plan). Samples were heated for 5 min
at 95C, loaded onto a 10% SDS polyacrylamide gel and
run at 30 mA with running buffer (25 mM Tris, 190 mM
glycine, 0.08% (w/v) SDS). SDS-PAGE gels were trans-
ferred overnight onto PVDF membranes (Millipore, Biller-
ica, MA) at 37 V in transfer buffer (20 mM Tris; 150 mM
glycine, 20% (v/v) methanol). Membranes were blocked in
5% non-fat dry milk (MARVEL, Dublin, Ireland) in phos-
phate buffered saline (PBS: 2.7 mM KCl, 137 mM NaCl,
1.5 mM KH2PO4, 9.2 mM Na2HPO4) before incubation
with the primary antibody diluted in the blocking solution.
Primary antibodies used were rabbit anti-P0 (1:200)
(Sigma-Aldrich), rat anti-MBP (1:500) (Millipore), rabbit
anti-c-jun (1:200) (Santa Cruz Biotechnology, Santa Cruz,
CA), rabbit anti-Notch-1 (1:500) (Santa Cruz), rabbit anti-
Cleaved Notch-1 (Val1744) (NICD) (1:500) (Cell Signal-
ing, Boston, MA), rabbit anti-Sox10 (1:1000) (Millipore).
Actin was used as the internal reference protein and
detected by a rabbit anti-actin (1:1500) (Millipore). Mem-
branes were incubated with appropriate HRP-conjugated
secondary antibodies (1:20,000) (Promega) and antibody
binding was revealed by using enhanced chemilumines-
cence (ECL) (Euroclone, Pero, Mi, Italy). The intensity of
the bands was evaluated by densitometric analysis using
the ImageQuant 5.2 program (Amersham Biosciences
Europe, Cologno Monzese, Italy). The optical density (OD)
of each protein band was normalized against the OD of the
actin band. The ratios from at least three independent west-
ern blots were averaged and the standard error of the mean
(SEM) calculated.
Immunocytochemistry
Schwann cells were plated onto 35-mm diameter dishes in
complete DMEM, containing 10% FBS and 2 mM forskolin,
and maintained for 48 h in either the presence or absence of
100 mM arecaidine. Cells were washed twice with PBS and
fixed for 20 min in 4% paraformaldehyde in PBS, at room
temperature (RT). After three washes in PBS, SCs were
incubated for 45 min in 10% normal goat serum (NGS)
Table 1 Primer Sequences Used in Real-Time PCR and RT-PCR Analysis
Gene Forward 50-30 Reverse 50-30
Krox20/Egr2 TGTGGCACTTTAATGGCTTG AGAACGAACGGAAGTGCAAT
Sox-10 ACTGGGAACAGCCAGTATATA ACCAAACTCCTCCTTTGCCA
Jagged-1 ATGGCCTCCAACGATACTCCT ACATGTACCCCCATAGTGGCA
Hes-1 GTCCCCGGTGGCTGCTAC AACACGCTCGGGTCTGTGCT
c-jun GATGGAAACGACCTTCTACGAC AGCGTATTCTGGCTATGCAGTT
GAPDH GTGCCAGCCTCGTCTCATAG TGATGGCAACAATGTCCACT
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(Vector Laboratories, Burlingame, CA) and 1% bovine
serum albumin (BSA) (Sigma-Aldrich) in PBS, and then
overnight at 4C with one of the following primary antibod-
ies: rabbit anti-N-CAM (1:100) (Millipore) or mouse anti-
N-cadherin (1:100) (Sigma-Aldrich), diluted in 1% NGS,
1% BSA in PBS. After two rinses (10 min each) in 1%
BSA in PBS, SCs were incubated for 1 h at RT with the
appropriate secondary antibodies: goat anti-rabbit IgG
Alexa 488 or goat anti-mouse IgG Alexa 594 (Promega),
diluted 1:250 in 1% BSA in PBS. After two rinses in 1%
BSA in PBS, cultures were mounted with glycerol/PBS
(3:1, v/v). Controls, obtained by omitting the primary anti-
body, were always immunonegative. Actin was visualized
by using phalloidin-TRITC conjugated, diluted 1:50 in 1%
BSA in PBS (Sigma) and nuclei were counterstained with
Hoechst 33588.
Cell Infection with Adenovirus
Expressing Notch-NICD
Recombinant adenoviruses expressing the constitutively
active form of Notch-1 (NICD) and green fluorescent pro-
tein (GFP) were previously described (Rangarajan et al.,
2001). Viruses were used at a multiplicity of infection of
50 MOI. SCs were infected with adeno-GFP and adeno-
GFP-NICD for 1 h in a serum free medium, which was sub-
sequently replaced with complete medium (10% FBS1 2
mM Fsk). During the following days some plates were
treated with arecaidine for 24 h and cells collected in
Laemmli buffer (Bio-Rad) (100 mL/33 105 cells).
RNAse Protection Assay (RPA)
Samples containing 8 mg of total RNA were dissolved in 20
mL of hybridization solution (80% formamide, 40 mM
PIPES, pH 6.4, 400 mM sodium acetate, pH 6.4, and 1 mM
EDTA) containing 150,000 cpm of each 32P-labeled cRNA
probes and 50,000 cpm of 32P-labeled cRNA 18 s probe.
cRNA antisense probes were generated by in vitro tran-
scription from pCRVR II-TOP0VR plasmids (Invitrogen, Life
Technologies Italia, Monza, Italy) containing inserts spe-
cific for P0 and PMP22 mRNA and for 18 s rRNA (310 bp
for P0, 415 bp for PMP22 and 290 bp for 18s rRNA). All
cRNA probes had a specific activity >108 cpm/mg. After
being heated at 85C for 10 min, probes were hybridized
overnight with the endogenous RNA at 45C. Samples
were then diluted with 200 mL of RNase digestion buffer
(300 mM NaCl, 10 mM Tris-HCl pH 7.4, 5 mM EDTA pH
7.4), containing a cocktail of RNase (1 mg/mL RNase A and
20 U/mL RNase T1; Ambion Life Technologies Italia,
Monza, Italy), diluted 1:400, and incubated for 30 min at
30C. Ten micrograms of proteinase K (Ambion) and SDS
(10 mL of a 20% stock solution) were added to samples
and incubated at 37C for 15 min. After incubation samples
were extracted with phenol-chloroform and precipitated
with ethanol. Pellets were dried and re-suspended in load-
ing buffer (80% formamide, 0.1% xylene cyanol, 0.1% bro-
mophenol blue, 2 mM EDTA), boiled at 95C for 5 min
and separated on a 5% polyacrilamide gel, under denaturing
conditions (7M urea). The protected fragments were visual-
ized by autoradiography and their size was determined by
using 32P-end labeled (T4 polynucleotide kinase) MspI-
digested pBR322 fragments.
Light Microscopy and Morphometric
Analysis of Sciatic Nerves
WT and M2/M4 knock-out (KO) mice were deeply anes-
thetized with a mixture of Zoletil (tiletamine chlorohydra-
te1 zolazepam chlorohydrate, 25 mg/kg b.w.) (Virbac,
France) and Rompun (xylazine, 8 mg/kg b.w.) (Bayer, Ger-
many), and perfused transcardially with a Ca21-free oxy-
genated Ringer’s variant, pH 7.3, followed by a fixative
composed by 2% freshly depolymerized paraformaldehyde
and 2.5% glutaraldehyde in 0.1M phosphate buffer (PB),
pH 7.4. After fixation, sciatic nerves were dissected and
placed in the same fixative overnight at 4C. Following a
rinse in PB, specimens were osmicated with 2% OsO4 in
0.1M PB (1 h at 4C), rinsed in distilled water, treated with
aqueous 2% uranyl acetate (1 h at 4C), rinsed again, dehy-
drated with a series of ascending ethyl alcohol and propyl-
ene oxide and embedded in Epon 812. Serial semithin
sections (2 mm) were cut at an Reichert-Jung ultramicro-
tome (Leica), stained with 0.1% toluidine blue in 0.1%
borax and permanently coverslipped with Eukitt balsam for
light microscopy evaluation. Images were acquired with a
Canon digital camera at 403 and then analyzed at a final
magnification of 15003 using the Pro Plus Imaging soft-
ware. For the morphometric investigation, we analyzed 4
WT and 4 M2/M42/2 mice, choosing three non-serial sec-
tions per animal. In each semithin section, 25 fields (corre-
sponding to at least 50% of the total nerve cross-sectional
area) were randomly selected (Mayhew and Sharma, 1984).
Number, size, g-ratio (i.e., the ratio axon/fiber diameters)
and the number of fibers with regular shapes (circularity
index, IC> 0.75) were assessed on at least 500 myelinated
fibers/section.
Transmission Electron Microscopy
From the same specimens used for semithin sections, ultra-
thin sections (50–60 nm) were cut, collected on single-hole
Formvar-coated copper grids, counterstained with 2% ura-
nyl acetate and 0.2% lead citrate, and viewed at an
EM208S transmission electron microscope (TEM), oper-
ated at 80 kV. Images were acquired by a Megaview III
camera and adjusted for contrast and brightness with Adobe
Photoshop software.
Scanning Electron Microscopy
SCs adherent onto coverslips were fixed in 2% glutaralde-
hyde in 0.1M PBS pH 7.4, for 4 h at 4C, and then rinsed
overnight in PBS. The following day, samples were rinsed
(3 3 15 min) in PBS 0.1M (pH 7.4) and post-fixed in 1%
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OsO4 in the same buffer for 1 h at 4
C. After a rinse (3 3
15 min) in 0.1M PBS, cells were dehydrated with a series
of ascending ethanol alcohol and critical point dried in liq-
uid CO2. Samples were mounted on aluminum stubs and
sputter coated with gold. The processed specimens were
investigated and photographed using a JEOL 6700F SEM
operated at 5 kV and an 8.3 mm working distance. Scan-
ning Electron microscope (SEM) images were collected
digitally.
Statistical Analysis
For both densitometric and morphometric analyses, one-
way ANOVA and Bonferroni’s multiple-comparisons post-
hoc test were used to evaluate statistical significance
between different experimental groups. Data were consid-
ered significant at *p< 0.05, **p< 0.01, and ***p< 0.001.
RESULTS
M2 Receptor Activation Regulates
Transcription Factors Modulating SC
Development
The transition from promyelinating to myelinating
SCs is regulated by several transcription factors, in
particular Sox10 that, in turn, plays a critical role in
the induction of the immediate early gene Krox20/
Egr2. Therefore, we first investigated, by real-time
RT-PCR, the expression level of sox10 mRNA fol-
lowing stimulation with 100 mM of M2 agonist are-
caidine. M2 receptor activation induced a significant
twofold increase in sox10 mRNA after both 24 h and
48 h of treatment versus the control (without arecai-
dine) [Fig. 1(A)]. Upregulation of the sox10 tran-
script matched a concomitant increase in the
corresponding protein levels [Fig. 1(B), upper panel:
representative western blot; lower panel: quantitative
analysis]. Sox10 transcript upregulation appears to
depend directly on M2 receptor activation, as it was
inhibited by incubating SCs with the M2 antagonist
gallamine (1026 M) (Supporting Information
Fig. 1B; upper panel: representative RT-PCR; lower
panel: densitometric analysis).
Since Krox20 is an immediate early gene poten-
tially regulated also by Sox10, SCs were treated with
arecaidine for short term (1 and 6 h) and krox20 tran-
script levels were analyzed by real-time RT-PCR. As
expected, krox20 mRNA began to increase signifi-
cantly, compared with untreated cells, after 30 min
[Fig. 1(C)], with a transient peak (about 130-fold) at
1 h after arecaidine treatment [Fig. 1(C)]. Consider-
ing the ability of Krox20 to downregulate the expres-
sion of the transcription factor c-jun, implicated in
the inhibition of SC differentiation and in the rescue
of their proliferative activity (Parkinson et al., 2004),
we also evaluated c-jun expression at both transcript
and protein level following arecaidine treatment (100
mM). After 1 h, c-jun transcript appeared to be down-
regulated when compared with untreated cells, as
indicated by RT-PCR analysis [Fig. 2(A), representa-
tive RT-PCR; Fig. 2B, quantitative analysis]. By
western blots, c-jun protein levels in untreated cells
corresponded to an intense immunoreactive band of
the predicted molecular mass [Fig. 2(C), first lane],
which was consistent with the state of proliferating
SCs (Arthur-Farraj, 2012). However, following stim-
ulation with arecaidine, the expression of c-Jun sig-
nificantly decreased after 24 h and disappeared after
48 h [Fig. 2(C), representative western blot; Fig.
2(D), densitometric analysis].
M2 Receptor Negatively Modulates
Notch-1/Jagged-1 Pathway
Notch-1 signaling is involved in the regulation of
transition from precursor to immature SCs and,
together with c-jun, controls SCs plasticity and dedif-
ferentiation after nerve injury (Woodhoo et al.,
2009). Therefore, we investigated whether Notch-1
signaling was affected by the M2 agonist arecaidine.
SC cultures were treated for 24 h with increasing
concentrations of arecaidine (10, 50, and 100 mM).
No significant changes in SC morphology were
observed after short-term arecaidine treatments [Fig.
3(A)]. Western blot analysis, performed in the same
experimental conditions, showed that full-length
Notch-1 expression was not modulated by arecaidine
[Fig. 3(B), upper row of the representative Western
blot shown in the upper panel], while expression of
the active form of Notch (Notch Intracellular
Domain; NICD) progressively decreased, reaching
undetectable levels in cells treated with 100 mM are-
caidine [Fig. 3(B), lower row in the upper panel],
which resulted in an almost fourfold decrease in the
densitometry results when compared with control
conditions [Fig. 3(B), lower panel]. To further vali-
date these findings, we evaluated the expression of
hes-1, the transcription factor downstream Notch sig-
naling. As expected, real-time RT-PCR analysis
showed a significant decrease in hes-1 transcript lev-
els following arecaidine treatment [Fig. 3(C)].
To investigate whether downregulation of the
Notch-1 pathway was dependent on the expression of
its specific ligands, we evaluated the expression of
Delta-1 and Jagged-1. Delta-1 was not detectable in
SCs in vitro (data not shown), but we found a consist-
ent expression of Jagged-1 that was significantly
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reduced 24 h after arecaidine treatment [Fig. 4(D)
representative Western immunoblot; Fig. 4(E), densi-
tometric analysis]. To evaluate whether decreased
expression of Jagged-1 was controlled by M2 recep-
tors directly or via Notch-1 activation, we infected
SCs with a recombinant adenovirus expressing the
construct GFP-NICD. Successful transfection was
evaluated analyzing the presence of GFP signal at the
fluorescence microscope [Fig. 4(A,B)]. Expression of
Notch-1 was then evaluated by western immunoblot
using an antibody that recognizes its carboxy-
terminus, common to both active and inactive forms
of Notch-1. Untreated cells expressed Notch-1 [Fig.
4(C), top left panel, first lane] and, as previously
demonstrated, arecaidine did not modulate this
expression [Fig. 4(C), top left panel, second lane].
When SCs were infected with the adenovirus contain-
ing the NICD fragment, an increase in Notch-1
expression, compared with uninfected cells, was
observed [Fig. 4(C), top right panel, first lane].
Again, arecaidine was unable to modulate this
expression [Fig. 4(C), top right panel, second lane].
Concerning Jagged-1 expression, we observed that in
cells infected with the control vector adeno-GFP
[Fig. 4(D), representative western blot; Fig. 4(F),
densitometric analysis], arecaidine treatment induced
a decrease in protein expression similar to that
observed in uninfected cells (control) [Fig. 4(D,E)].
Conversely, when SCs were infected with the adeno-
GFP-NICD, no difference in Jagged-1 expression
was observed after arecaidine treatment [Fig.
4(D,F)], suggesting that expression of Jagged-1 was
directly controlled by Notch-1.
M2 Receptor Activation Induces
Morphological Changes in SCs
When SCs arrest their proliferation and begin to dif-
ferentiate, they undergo significant changes in cell
Figure 1 Sox10 and Krox20 expression in cultured SCs. A: Real-time RT-PCR analysis of sox10
expression in control and 100 mM arecaidine-treated SCs (24 and 48 h). Transcript levels were nor-
malized against the housekeeping gene GAPDH, and arecaidine-treated samples were normalized
to control levels. B: Western immunoblot and densitometric analysis of Sox10 protein levels in
control and 100 mM arecaidine-treated SCs (24 and 48 h). In the upper panel, a representative west-
ern blot is shown. The graph below reports the densitometric analysis of Sox10 immunopositive
bands. Actin was used as the internal reference protein. C: Real-time RT-PCR analysis of krox-20
expression in control and 100 mM arecaidine-treated (30 min, 1 h, and 6 h) SCs. Transcript levels
were normalized against the housekeeping gene GAPDH, and arecaidine-treated samples were nor-
malized to control. Data represent the mean6 SEM of at least three independent experiments;
**p< 0.01; ***p< 0.001, by ANOVA and Bonferroni’s post-hoc test.
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morphology due to modification of cytoskeletal orga-
nization and differential expression and/or distribu-
tion of adhesion molecules (Morgan et al., 1991;
Fernandez-Valle, 1997; Li et al., 2003). To confirm
the role of M2 signaling on SC differentiation, we
evaluated morphological changes in SCs cultured in
the absence or presence of arecaidine. As observed
by SEM, when SCs were cultured in DMEM with
addition of forskolin, a condition that promotes cell
proliferation (Kim et al., 1997; Monje et al., 2006),
they showed a classic bipolar morphology [Fig.
5(A,B)]. However, in these experimental conditions,
some photographic fields showed several cells with a
rounded morphology, typically associated to cells
that enter the mitotic phase [see box in Fig. 5(A)].
Conversely, according with our previous data (Loreti
et al., 2007), when SCs were cultured in the presence
of arecaidine (100 mM) for 48 h, they arrested their
proliferation and appeared as flat cells juxtaposed to
one another [Fig. 5(C,D)]; in this experimental condi-
tion the presence of “rounded morphology cells” was
lacking. Although SCs changed their morphology
after arecaidine treatment, the expression of SC
markers (i.e., GFAP, S100b, p75) remained unmodi-
fied (see Supporting Information Fig. 3).
Due to these findings, we next assessed the expres-
sion and distribution of adhesion molecules such as
N-CAM and N-cadherin. Albeit N-CAM was
expressed at low levels, both proteins were distrib-
uted similarly in untreated cells, as observed by
immunocytochemical analysis [Fig. 5(G,I)]. After 48
h of arecaidine treatment, both adhesion molecules
clustered in restricted areas of contact between neigh-
boring cells [Fig. 5(H,L)]. Similarly, in untreated
cells actin filaments appeared organized to form
stress fibers, which re-distributed under the plasma
membrane following arecaidine treatment [Fig.
5(E,F)].
M2 Receptor Regulates SC Myelination
To confirm the ability of the M2 agonist arecaidine to
modulate SC differentiation towards a myelinating
phenotype, we analyzed the expression of several
myelin proteins, namely P0, PMP22, and MBP. As
expected, muscarine (100 mM), a non-selective mus-
carinic agonist, induced a faint increase in the
PMP22 transcript, but not in the P0 one. On the other
hand, arecaidine (100 mM) induced a strong increase
in both P0 and PMP22 mRNAs [Fig. 6(A,B),
Figure 2 c-jun expression in cultured SCs. (A,B) RT-PCR analysis of c-jun transcript levels in
control and 100 mM arecaidine-treated SCs (1 h) (A), and relative densitometric analysis (B). Lev-
els of mRNA transcripts were normalized against the housekeeping gene GAPDH, and arecaidine-
treated samples were normalized to control. (C,D) Western blot analysis of c-Jun protein levels in
control and 100 mM arecaidine-treated SCs (24 and 48 h) (C), and relative densitometric analysis
(D). Actin was used as internal reference protein. Data represent the mean6 SEM of at least three
independent experiments; *p< 0.05; **p< 0.01, by ANOVA and Bonferroni’s post-hoc test.
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densitometric analysis]. In agreement with these
changes in mRNA expression, P0 and MBP protein
levels increased after arecaidine treatment [Fig. 6(C),
representative Western immunoblot; Fig. 6(D), densi-
tometric analysis].
SC engagement into a myelinating phenotype was
verified by both light and electron microscopy, and
by morphometric analysis of toluidine blue stained
semithin sections of sciatic nerve from double M2/
M42/2 mice. When compared with wild type (WT),
sciatic nerves from M2/M42/2 mice showed several
alterations in myelin sheath organization of the
medium/large-sized axons [Fig. 7(A), WT mice; Fig.
7(B), KO mice]. We identified three main types of
morphological abnormalities: degenerating axons,
myelin inclusions and loose myelin sheaths. These
observations were supported by morphometric analy-
sis, which underlined a significant increase in the
number of degenerating axons and myelin inclusions,
and an even more significant increase in the number
of axons surrounded by loose myelin (p< 0.001, M2/
M42/2 vs. WT) [Fig. 7(C)]. The area occupied by
myelin sheath was also significantly increased in M2/
M42/2 mice when compared with WT [Fig. 7(D)],
possibly due to the presence of loose myelin, which
contains large portions of cytoplasm not properly
extruded [Fig. 7(E)].
TEM analysis confirmed the presence of myelin
sheaths with different degrees of compactness (Fig.
8). Although myelin sheaths can assume bizarre con-
figurations also in WT animals, several axons in M2/
M42/2 mice displayed irregular and multi-lobed
ensheathments, which intruded in the inner space
occupied by the axon shaft itself. As a consequence,
depending on the plane of cut, we could observe
peculiar myelin figures, that is, circular multilamellar
Figure 3 Activation of the Notch-1 pathway. A: SCs maintained in vitro in the absence (control)
or in the presence of 10, 50, or 100 mM arecaidine for 24 h (scale bar5 100 mM). B: Western blot
analysis of full length-Notch-1 and Notch-NICD protein levels in control and arecaidine-treated
(10, 50, or 100 mM) SCs. Representative western blots and relative densitometric analyses are
shown in the upper and lower panel, respectively. Full-length Notch was used as the internal refer-
ence protein. C: Real-time RT-PCR analysis of hes-1 expression levels in control and 100 mM
arecaidine-treated SCs (24 and 48 h). Transcript levels were normalized against the housekeeping
gene GAPDH and arecaidine-treated samples were compared with control. Data represent the
mean6 SEM of at least three independent experiments; **p< 0.01, by ANOVA and Bonferroni’s
post-hoc test.
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bodies seemingly floating within the axoplasm [Fig.
8(A)]. In other axons, clear signs of progressive mye-
lin sheath disorganization and degeneration were
observed, which eventually led to axon degeneration
and death. In Figure 8(B–G), we show a possible
sequence of this SC-axon degeneration process: a)
myelin sheath decompacting and presence of interca-
lating portions of cytoplasm between the lamellae
[Fig. 8(B)]; b) signs of degeneration, with accumula-
tion of cellular debris within the cytoplasm, while
axons detach from myelin and are pushed aside [Fig.
8(C)]; c) axon caliber progressively reduces, while
myelin sheaths decrease in thickness, subdividing in
different compartments [Fig. 8(D)], until complete
degeneration of both SC and axons occurs [Fig. 8(E–
G)]. Other atypical aspects observed were abnormally
thick myelin sheaths [Fig. 8(H)], which seemed
to suffocate the inner axons until they degenerated
Figure 4 Overexpression of Notch-NICD in cultured SCs by adenovirus infection. (A,B) Repre-
sentative fluorescence microscope images showing adenovirus-infected SCs expressing the GFP-
NICD construct in control conditions (A) and after 100 mM arecaidine treatment (24 h) (B) (scale
bar5 50 mm). (C) Western immunoblot analysis of Notch-1 protein levels in control and 100 mM
arecaidine-treated (24 h) SCs, without adenoviral infection and 1 h after infection with the GFP-
Notch/NICD adenovirus (with or without 100 mM arecaidine treatment for 24 h). Notch protein lev-
els increased in infected cells. (D) Representative western blot analysis of Jagged-1 protein levels
in SCs maintained in control conditions (10% FBS1 2 mM fsk) without adenovirus or infected with
the adenovirus-GFP only, or treated with the adenovirus GFP-NICD, in the absence or presence of
100 mM arecaidine, for 24 h. (E) Densitometric analysis of the bands immunopositive for Jagged-1
in protein extracts from control SCs (without infection); (F) densitometric analysis of the bands
immunopositive for Jagged-1 in protein extracts from SCs infected with either the adenovirus-GFP
or the adenovirus GFP-NICD constructs. Actin was used as the internal reference protein. Data rep-
resent the mean6 SEM of at least three independent experiments; **p< 0.01, by ANOVA and
Bonferroni’s post-hoc test. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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[Fig. 8(I)]. Axons displaying apparently healthy mye-
lin sheaths could have eventually undergone degener-
ation, characterized by progressive axoplasm
compaction. Nonetheless, as evidenced by light
microscopy, numerous axons also displayed healthy
myelin sheaths [Fig. 8(J)], as those seen in WT mice.
DISCUSSION
Development of SCs strictly depends on their interac-
tions with neuronal axons. Although members of the
NRG family have been described as the main regula-
tory molecules controlling the SC switch from a pro-
liferative to a myelinating phenotype (Syed et al.,
2010; Arthur-Farray et al., 2011), several evidences
suggest that NRG signals alone are not sufficient
(Jessen and Mirsky, 2010; Arthur-Farraj et al., 2011).
Moreover, transcription factors ruling SC prolifera-
tion and differentiation have been largely described
(Parkinson et al., 2004; Woodhoo et al., 2009; Dod-
drell et al., 2012; Fontana et al., 2012).
An important role of neurotransmitters in the con-
trol of neuron-glia cell interactions in both CNS and
PNS is emerging. Several neurotransmitters, that is,
GABA, ATP and adenosine, have been demonstrated
to be involved in the modulation of glial cell physiol-
ogy (Stevens et al., 2002; Magnaghi et al., 2004; Pro-
cacci et al., 2013). Among these, also ACh could
play a role, since expression of different ACh recep-
tors has been reported in different types of glial cells
(OLs, astrocytes and SCs) (Murphy et al., 1986;
Ragheb et al., 2001; Loreti et al., 2006; De Angelis
et al., 2012). In this context, we demonstrated before
that ACh controls OL and SC proliferation through
activation of M3 and M2 muscarinic receptors,
respectively (Loreti et al., 2007; De Angelis et al.,
2012). In particular, we showed that activation of the
M2 receptor in SCs (the most abundant receptor sub-
type expressed in these cells) with the agonist arecai-
dine, caused a reversible arrest of cell cycle
progression, with accumulation of SCs in the G1
phase (Loreti et al., 2007). The effect of arecaidine
could be counteracted by gallamine, an antagonist of
Figure 5 Morphological analysis by SEM of SCs maintained in control condition (10% FBS1 2
mM fsk) (A,B) and after 48 h treatment with 100 mM arecaidine (C,D). The box in panel (A) shows
a representative field of untreated cells in active mitosis. (E,F) SC actin staining with phalloidin-
TRITC conjugate in control conditions (E) and after treatment with 100 mM arecaidine (F), showing
redistribution of actin stress fibers after M2 agonist induction. (G–L) Immunocytochemistry for N-
CAM (G,H) and N-caderin (N-cad, I,L) in control condition (10% FBS1 2 mM fsk) (G,I) and after
100 mM arecaidine treatment (48 h) (H,L). After treatment, both adhesion molecules aggregated in
discrete areas at cell–cell points of contact (scale bar5 15 mm). [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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the M2 receptor. In fact, co-treatment of SCs with
gallamine and arecaidine rescued cell proliferation,
demonstrating that arecaidine-mediated effects were
dependent on M2 receptor activation (Loreti et al.,
2007). Considering the ability of SCs to switch from
a proliferative to a differentiated phenotype, a phe-
nomenon that occurs during development and nerve
fiber repair, we investigated whether blocking cell
proliferation with the M2 agonist arecaidine could
also modulate SC differentiation. To test this hypoth-
esis, we evaluated the expression of some transcrip-
tion factors involved in SC differentiation (i.e.,
Krox20 and Sox10) or proliferation (i.e., c-jun,
Notch-1). Sox10 and Krox20/egr-2 have been identi-
fied as main transcriptional regulators of the myelina-
tion process. Although Sox10 was expressed early
during SC proliferation, its increased levels may reg-
ulate cell entry in a promyelinating stage (Svaren and
Meijer, 2008). The expression of these transcription
factors was evaluated in SC cultured in either
absence or presence of arecaidine (100 mM). Short-
term arecaidine stimulation (30 min or 1 h) had no
effect on the levels of sox10 transcript (Supporting
Information Fig. 1A). Arecaidine induced the upregu-
lation of both Sox10 transcript and protein levels
after prolonged treatments in a time-dependent man-
ner (24 and 48 h). This increase was directly modu-
lated by M2 receptor activation, as the M2 antagonist
Figure 6 A: Expression of myelin mRNA transcripts for the PMP22 and P0 proteins in SCs main-
tained in the absence or presence of 100 mM arecaidine (24 h). P0 and PMP22 mRNA levels were
analyzed by RNAse protection assay. 18S was used as the housekeeping gene. B: Densitometric
analysis of P0 and PMP22 mRNA expression. The intensity of the PM22 and P0 bands was normal-
ized against that of 18 s. C: Western blot (upper panel) analysis of P0 protein levels in SCs main-
tained in the absence or in the presence 100 mM arecadine (48 h) and relative densitometric
analysis (lower panel). D: Western blot (upper panel) analysis of MBP protein levels in SCs main-
tained in the absence or in the presence 100 mM arecaidine (24 h and 48 h) and relative densitomet-
ric analysis (lower panel). Actin was used as the internal reference protein. Data represent the
mean6 SEM of at least three independent experiments; *p< 0.05, **p< 0.01, by ANOVA and
Bonferroni post-hoc test.
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gallamine (1026 M) counteracted the arecaidine-
induced increase in sox10 transcript (Supporting
Information Fig. 1B).
In contrast, krox20 was upregulated after 30 min of
arecaidine treatment, further increased after 1 h
(p< 0.001, 1 h arecaidine vs. control) and then rap-
idly decreased after 6 h, according to the typical pat-
tern of induction of immediate early genes. After
prolonged treatment with arecaidine (24 or 48 h),
krox20 mRNA was expressed in SCs, but its levels
were not modified by M2 receptor activation (Sup-
porting Information Fig. 2). Considering that mem-
bers of the Krox(Egr) transcription factor family are
enhanced by muscarinic receptor engagements (Ebi-
hara and Saffen, 1997; von der Kammer et al., 1998;
Salani et al., 2009), the early increase in Krox20
expression induced by arecaidine may depend on a
direct regulation by M2 receptor activation rather
than by Sox10 modulation. Although krox20 mRNA
expression is evident after prolonged arecaidine treat-
ment, it did not increase as a consequence of the
arecaidine-induced upregulation of Sox10 expres-
sion, suggesting that cholinergic stimulation alone
may not be enough to sustain an extended activation
of Krox20 in SCs.
Krox20 can modulate SC differentiation also by
inducing cell cycle arrest, antagonizing c-jun expres-
sion (Parkinson et al., 2004). In fact, c-jun is typically
downregulated in early post-natal SCs to allow mye-
lination (Jessen and Mirsky, 2008), and it is rapidly
upregulated after nerve injury, to promote an imma-
ture phenotype (De Felipe and Hunt, 1994; Stewart,
1995; Shy et al., 1996; Arthur-Farraj et al., 2012). As
myelination is associated with c-jun downregulation,
Figure 7 Semithin transverse sections (2-mm thick) of sciatic nerves of WT (A) and M2/M42/2
mice (B) stained with toluidine blue (scale bar5 15 mm). In KO mice, several morphological altera-
tions in myelin organization and numerous degenerating axons are evident (red arrows: degenerat-
ing axons; yellow arrows: myelin inclusions; orange arrows: loose myelin). (C) Quantitative
analysis of the most common morphological alterations observed in sciatic nerve semithin sections
from WT and KO mice. The graph reports the percentage of degenerating axons, axons with myelin
inclusions and axons with loose myelin. (D) Quantitative analysis of the area occupied by the mye-
lin coat surrounding WT and KO mouse axons. Data represent the mean6 SEM; ***p< 0.001,
**p< 0.01, by ANOVA and Bonferroni post-hoc test. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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and considering that early Krox20 upregulation was
induced by arecaidine, we investigated the expression
of c-jun after arecaidine stimulation. As expected,
expression of the c-jun transcript was decreased 1 h
after arecaidine treatment, while protein expression
was reduced after 24 h and abolished after 48 h.
Krox20 is also able to downregulate Notch-1
expression (Taveggia et al., 2010). In the PNS Notch-
Figure 8
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1 is expressed by SCs, whereas its ligand Jagged-1 is
present in both SCs and axons. Notch-1 promotes SC
transition from a precursor state to an immature phe-
notype (Woodhoo et al., 2009). As a matter of fact,
overexpression of the active intracellular domain of
Notch1 (NICD) delays myelination, while Notch-1
inactivation accelerates it (Woodhoo et al., 2009; Jes-
sen and Mirsky, 2010). Analyzing Notch-1 and
NICD expression in cultured SCs after arecaidine
treatment, we observed that while the expression of
full-length Notch-1 was not modulated, that of NICD
was progressively reduced in a dose dependent man-
ner. Recently, it has been demonstrated that, in mye-
linating SCs, Krox20 suppresses the formation of the
NICD fragment (Woodhoo et al., 2009), suggesting
that the observed arecaidine-induced NICD downreg-
ulation may be dependent on Krox20 activation.
In agreement with the decrease in NICD expres-
sion, we observed a decline in mRNA levels of hes-1,
the canonical transcription factor downstream to the
Notch pathway. Arecaidine treatment downregulated
also the expression of Jagged-1, a ligand of Notch-1.
However, when the active form of Notch was over-
expressed in SCs transduced with an adenovirus
expressing the GFP-NICD fragment, we did not
observe a downregulation of Jagged-1 after arecai-
dine treatment, compared with uninfected SCs and to
cells infected with a control adenovirus containing a
GFP-empty construct. In fact, Jagged-1 expression
was unchanged after overexpression of the NICD
fragment. These data suggest that the levels of
Jagged-1 are directly controlled by Notch-1 and indi-
rectly modulated by arecaidine, through NICD
downregulation.
Activation of M2 cholinergic receptor, by posi-
tively regulating Sox10/Krox20 expression and
antagonizing c-jun/Notch-1 activity, provides a
molecular mechanism promoting the exit of SCs
from the cell cycle, in agreement to our previous data
(Loreti et al., 2007). To test the ability of M2 receptor
to induce SC differentiation and considering that
genes encoding myelin proteins, such as P0 and
MBP, have consensus binding sites for Sox10 and
Krox20 (Peirano et al., 2000; LeBlanc et al., 2005),
we attempted to demonstrate that M2 receptor activa-
tion can also modulate myelin protein expression, at
both transcriptional and post-transcriptional levels,
possibly as a consequence of Sox10 and Krox20
upregulation. However, the increase in myelin pro-
tein expression, although significant, appeared mod-
est. This may be in part dependent on the
experimental conditions. In fact, when SCs are cul-
tured in vitro, in the absence of axons, they are not
able to achieve a complete myelination process
because of lack of axon-derived signals (i.e., NRG1
Type III). Nevertheless, the increased levels of mye-
lin proteins after arecaidine treatment may represent
an initial signal of SC progression towards a myeli-
nating phenotype and myelin organization.
This hypothesis is supported by our observations
on M2/M42/2 mice. Sections of sciatic nerve from
WT and M2/M42/2 mice, where M2 receptor signal
transduction is absent, were analyzed for myelin
organization. Since SCs do not express M4 receptors,
as previously demonstrated (Loreti et al., 2006), we
infer that the observed alterations mainly depend on
the lack of M2 receptor signaling. Light and electron
microscopic morphological analysis, along with mor-
phometric evaluation of some axonal parameters,
showed that, in KO mice, myelinated axons undergo
significant alterations in myelin organization (e.g.,
myelin inclusions and loose myelin). In addition, SC
treatment in vitro with arecaidine induced significant
changes in cell morphology towards a differentiating
phenotype, as evaluated by SEM analysis. This dif-
ferentiation was accompanied by a re-arrangement of
Figure 8 Electron micrographs showing different degrees of SC-axon alteration in M2/M4 double
KO mice. (A) Peculiar myelin conformation, in which the sheath repeatedly protrudes in the inner
space occupied by the axon (a). The myelin sheath itself displays different degrees of compaction.
(B) The myelin sheath has been divided in two by a large portion of Schwann cell cytoplasm (sc).
(C) Schwann cell (sc) cytoplasm is starting to accumulate cellular debris, while the surrounded
axon (a) has detached from myelin. (D) A Schwann cell (external cytoplasm indicated by sc) mye-
lin sheath is dividing in thin layers formed by highly compact myelin separated by large empty
spaces (asterisk), while the inner axon is reduced in caliber. (E) Degenerating Schwann cell (sc),
for which a residue of the former myelin sheath is still present in the place of the degenerated axon.
(F,G) Sites of degenerated Schwann cells and axons are identifiable by small remnants of a few
loose myelin lamellae (F) and empty ghosts surrounded by the previous Schwann cell basal lamina
(bl). (H) Small axon (a) surrounded by an abnormally thick myelin sheath. Surrounding axons
appear normal. (I) Degenerated small axon surrounded by a thick-type myelin sheath with different
degrees of compaction. (J) Large axon (a) with an apparently healthy myelin sheath, displays an
initial collapse of the axoplasm (asterisk), presumably represented by compacted mitochondria.
Scale bar: (C,I): 35 mm; (A,B,D–H,J): 50 mm.
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actin stress fibers (evaluated by phalloidin labeling),
which relocated under the plasma membrane, and a
re-distribution of adhesion molecules (i.e., N-CAM
and N-cadherin, evaluated by immunocytochemis-
try), which clustered in discrete areas where cell-to-
cell contacts were formed. These dynamic changes
indicate that both the cytoskeleton and adhesion
molecules contribute to stabilize new myelinic
structures (Fernadez-Valle et al., 1997; Tricaud
et al., 2005).
Together, our data demonstrate that ACh repre-
sents an additional molecule active in regulating
axon-SC cross-talk. As recently demonstrated, ACh
can be released along cholinergic axons (Corsetti
et al., 2012) and, therefore, contribute to the modu-
lation of axon-ensheathing, SC proliferation and dif-
ferentiation. Lack or low levels of ACh, together
with high levels of NRG1, may favor SC prolifera-
tion, while high levels of ACh would arrest SC pro-
liferation and direct them to a differentiation
program towards a myelinating phenotype. The
effect of the M2 agonist arecaidine on the block of
SC proliferation is reversible (Loreti et al., 2007),
further supporting the idea that ACh does not coun-
teract SC plasticity, but may contribute to its modu-
lation. This ability appears relevant not only during
SC development, but also after cholinergic nerve
injuries, where axon damage and the following
reduction in ACh release may contribute to the res-
cue of SC proliferation.
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